Day: April 15, 2024

Tozier is strategic advisor to the CEO, and former executive vice president and chief financial officer of Albemarle Corporation WILMINGTON, Del., April 15, 2024 (GLOBE NEWSWIRE) — Effective today, Ashland Inc. (NYSE: ASH) has announced the appointment of Scott A. Tozier, strategic advisor to the CEO and former executive vice president and chief financial officer of Albemarle Corporation to its Board of Directors. Tozier will serve on the Board’s Audit Committee and Environmental, Health, Safety and Quality Committee, each also effective April 15, 2024. Prior to Albemarle, Tozier held several leadership positions at Honeywell International, Inc. and served on the Board of Directors for Garrett Motion, Inc. Tozier is an experienced global executive with strong industry leadership in financial management, mergers and acquisitions,...

At the end of March 2024, the net asset value (NAV) of UAB “Atsinaujinančios energetikos investicijos” including success fee-accrual decreased to EUR 114,055,438 compared to the previously determined NAV at the end of December 2023 which amounted to EUR 115,325,513. The share price including success fee-accrual decreased to EUR 1.9445 compared to the previously determined share price which at the end of December 2023, amounted to EUR 1.9661. The pro-forma internal rate of return (IRR) since inception including success fee-accrual decreased to 9.48% compared to the previously announced IRR of December 2023, which amounted to 11.15% At the end of March 2024, the NAV excluding success fee accrual decreased to EUR 114,996,122 compared to the previously determined NAV at the end of December 2023, which amounted to EUR 117,108,358. The share...

                                                                       Amsterdam, 15 April 2024 EXOR N.V. ANNOUNCES THE RESTART OF THE ANNOUNCED SHARE BUYBACK PROGRAM Exor N.V. (the “Company”) announces today that it will restart the share buyback program announced on 13 September 2023 (the “Program”) for the remaining amount of up to € 250 million of ordinary shares to reduce Exor’s share capital in line with the announcement made on 13 September 2023. The Company will start on 15 April 2024 with a first tranche of purchases up to €125 million, which is expected to complete by September 2024, or earlier if the maximum amount has been reached (the “First Tranche”). The First Tranche will be executed in compliance with applicable rules and regulations, including the Market Abuse Regulation 596/2014 and the Commission Delegated...

The interim report for the first 6 months of the year will be announced in accordance with the year’s financial calendar on 2 May 2024. After 6 months, revenue of DKK 469 million against DKK 492 million in the same period of 2022/23 has been realised, which is above the expectations for the period. The revenue development is primarily driven by growth in the Group’s global fabric business, including the SampleMaster business unit, while the upholstering units (FurnMaster), as expected, realize a slight revenue decline compared to the same period last year. Under the given market challenges, management assesses that the revenue development indicates a strong competitiveness and market position for the Group. The calculated and preliminary results for the first 6 months of the year show an EBIT result of DKK 10.5 million compared...

SINGAPORE, April 15, 2024 (GLOBE NEWSWIRE) — Valeura Energy Inc. (TSX:VLE, OTCQX:VLERF) (“Valeura” or the “Company”), the upstream oil and gas company with assets in the Gulf of Thailand and the Thrace Basin of Türkiye, is pleased to announce three oil discoveries on its assets in the offshore Gulf of Thailand. Sean Guest, President and CEO commented: “I am pleased to announce that our exploration drilling campaign has resulted in three new oil discoveries, one in the Nong Yao D area, and two in the north-east portion of the Wassana concession.  As we continue to pursue adding value through growth, near-field exploration forms an important part of sizing up the organic potential of our assets. With successful results like these, the opportunity set before us is continuing to expand.    Following this...

EfTEN Real Estate Fund AS (trading code EFT1T, ISIN kood EE3100127242) will fix the list of shareholders for dividend distribution on 17.04.2024 at the end of of the working day of the registrar of the settlement system of the fund’s securities. Proceeding from the above, the ex-date is 16.04.2024. From that date the new owner of the shares is not entitled to dividends for the year 2023. EfTEN Real Estate Fund AS will distribute dividends in the amount of 1 euro per share on 24.04.2024. Viljar ArakasMember of the Management BoardPhone 655 9515E-mail: viljar.arakas@eften.ee  

Press release – Neuilly-sur-Seine, Monday, April 15, 2024 – 7.30 am ARGAN launches a new 18,000 sq.m Aut0nom® labelled project in Chartres Credit: A26 Architectures The success of Aut0nom® cannot be denied with a new project launched by ARGAN in Chartres. Work on this new 18,000 sq.m platform has started in the Jardin d’Entreprises economic activity zone. Connected by the A11 motorway, the Chartres ring road and tomorrow by the future A154 motorway, this area is the economic heart of the Chartres Metropolitan area. This new state-of-the-art logistics site will be operated under a fixed-term ten-year lease in future state of completion. The future site will be made up of three cells: two with controlled temperatures (15°C/25°C) and one refrigerated (2°C/8°C). It will bring together all the future operator’s logistics activities on...

Columvi, in combination with chemotherapy, demonstrated a statistically significant improvement in overall survival for people with relapsed or refractory diffuse large B-cell lymphoma Data from the STARGLO study will be submitted to health authorities and presented at an upcoming medical meetingBasel, 15 April 2024 – Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the Phase III STARGLO study met its primary endpoint of overall survival. The study demonstrated that people with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), who have received at least one prior line of therapy and are not candidates for autologous stem cell transplant, lived longer when treated with Columvi® (glofitamab) in combination with gemcitabine and oxaliplatin (GemOx) versus MabThera®/Rituxan® (rituximab) in combination with GemOx....